C
Carlos Cordon-Cardo
Researcher at Icahn School of Medicine at Mount Sinai
Publications - 620
Citations - 91832
Carlos Cordon-Cardo is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: Cancer & Prostate cancer. The author has an hindex of 144, co-authored 589 publications receiving 84862 citations. Previous affiliations of Carlos Cordon-Cardo include The Rogosin Institute & Erasmus University Rotterdam.
Papers
More filters
Journal ArticleDOI
Molecular pathways of urothelial development and bladder tumorigenesis
Mireia Castillo-Martin,Josep Domingo-Domenech,Orit Karni-Schmidt,Tulio Matos,Carlos Cordon-Cardo +4 more
TL;DR: A model for bladder tumor progression has been proposed in which 2 separate genetic pathways characterize the evolution of early bladder neoplasms, and it is proposed that 2 distinct progenitor cells are responsible for basal/intermediate cells and "umbrella" cells, respectively.
Journal ArticleDOI
Ku70: A Candidate Tumor Suppressor Gene for Murine T Cell Lymphoma
Gloria C. Li,Honghai Ouyang,Xiaoling Li,Hatsumi Nagasawa,John B. Little,David J. Chen,C. Clifton Ling,Zvi Fuks,Carlos Cordon-Cardo +8 more
TL;DR: It is shown that Ku70 deficiency facilitates neoplastic growth and a novel role of the Ku70 locus in tumor suppression is suggested, which is thought to be related to B but not T lymphocyte maturation.
Journal Article
Expression of Lewisa, Lewisb, X, and Y blood group antigens in human colonic tumors and normal tissue and in human tumor-derived cell lines.
Junichi Sakamoto,Koichi Furukawa,Carlos Cordon-Cardo,Beatrice W.T. Yin,Wolfgang Rettig,Herbert F. Oettgen,Lloyd J. Old,Kenneth O. Lloyd +7 more
TL;DR: Serological and immunopathological analysis of the expression of Lea, Leb, X, and Y blood group antigens on cell lines and tissues demonstrated the unexpected ability of tumors of nonsecretors to express Leb and/or Y antIGens and provide possible targets for immunodiagnosis and therapy.
Journal ArticleDOI
Massive parallel sequencing uncovers actionable FGFR2 – PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma
Daniela Sia,Bojan Losic,Agrin Moeini,Laia Cabellos,Ke Hao,Kate Revill,Dennis M. Bonal,Oriana Miltiadous,Zhongyang Zhang,Yujin Hoshida,Helena Cornella,Mireia Castillo-Martin,Roser Pinyol,Yumi Kasai,Sasan Roayaie,Swan N. Thung,Josep Fuster,Myron Schwartz,Samuel Waxman,Carlos Cordon-Cardo,Eric E. Schadt,Vincenzo Mazzaferro,Josep M. Llovet +22 more
TL;DR: It is demonstrated that the chromosomal translocation t(10;12)(q26;q12) leading toFGFR2-PPHLN1 fusion possesses transforming and oncogenic activity, which is successfully inhibited by a selective FGFR2 inhibitor in vitro.
Journal ArticleDOI
Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC.
Alvoro S. Sarkis,Dean F. Bajorin,Victor E. Reuter,Harry W. Herr,George J. Netto,Zuo-Feng Zhang,Paul K. Schultz,Carlos Cordon-Cardo,Howard I. Scher +8 more
TL;DR: In this article, the prognostic role of p53 nuclear overexpression in muscle-invasive bladder cancer was examined, and the results showed that patients whose tumors had p53 overexpressions had a significantly higher proportion of cancer deaths.